Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

November 24, 2021 updated by: Arena Pharmaceuticals
The purpose of this study is to determine whether etrasimod (APD334) is a safe and effective treatment for ulcerative colitis after 52 weeks of treatment.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

118

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Kingswood, Australia, 2747
        • Arena 1604
      • Randwick, Australia, 2031
        • Arena 1605
      • Subiaco, Australia, 6008
        • Arena 1607
  • Austria
      • Wien, Austria, 1090
        • Arena 1490
  • Belgium
      • Edegem, Belgium, 2650
        • Arena 1472
      • Kortrijk, Belgium, 8500
        • Arena 1464
      • Leuven, Belgium, 3000
        • Arena 1473
  • Bulgaria
      • Ruse, Bulgaria, 1407
        • Arena 1421
      • Sofia, Bulgaria, 1407
        • Arena 1417
      • Sofia, Bulgaria, 1527
        • Arena 1410
      • Sofia, Bulgaria, 1784
        • Arena 1409
      • Sofia, Bulgaria, 1797
        • Arena 1407
      • Varna, Bulgaria, 9010
        • Arena 1425
  • Canada
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3A 1R9
        • Arena 1202
    • Nova Scotia
      • Bridgewater, Nova Scotia, Canada, B4V 3N2
        • Arena 1210
    • Ontario
      • London, Ontario, Canada, N6A 4G5
        • Arena 1206
      • Sudbury, Ontario, Canada, P3E 1H5
        • Arena 1208
      • Sudbury, Ontario, Canada, P3E 6C3
        • Arena 1209
      • Toronto, Ontario, Canada, M5G 1X5
        • Arena 1204
  • Czechia
      • Praha 4, Czechia, 140 59
        • Arena 1455
  • France
      • Amiens Cedex 1, France, 80054
        • Arena 1443
      • Clichy, France, 92110
        • Arena 1418
      • Lille Cedex 1443, France, 59037
        • Arena 1437
      • Paris, France, 75010
        • Arena 1476
      • Pierre-Benite, France, 693110
        • Arena 1480
      • Saint-Etienne Cedex 1, France, 42055
        • Arena 1423
      • Vandoeuvre-les-Nancy, France, 54511
        • Arena 1457
  • Germany
      • Hamburg, Germany, 20249
        • Arena 1479
      • Hamburg, Germany, 22559
        • Arena 1422
      • Hanover, Germany, 30625
        • Arena 1470
      • Kiel, Germany, 24105
        • Arena 1446
      • Leipzig, Germany, 04103
        • Arena 1489
      • Oldenburg, Germany, 26123
        • Arena 1497
      • Ulm, Germany, 89073
        • Arena 1444
  • Hungary
      • Bekescsaba, Hungary, 5600
        • Arena 1478
      • Budapest, Hungary, 1036
        • Arena 1431
      • Budapest, Hungary, 1062
        • Arena 1471
      • Budapest, Hungary, 1062
        • Arena 1492
      • Debrecen, Hungary, 4025
        • Arena 1505
      • Debrecen, Hungary, 4032
        • Arena 1474
      • Szombathely, Hungary, 9700
        • Arena 1477
  • Israel
      • Beer Sheva, Israel, 84101
        • Arena 1705
      • Haifa, Israel, 31096
        • Arena 1702
      • Holon, Israel, 58100
        • Arena 1706
      • Jerusalem, Israel, 91031
        • Arena 1704
      • Petah-Tikva, Israel, 49100
        • Arena 1703
  • Korea, Republic of
      • Daegu, Korea, Republic of, 42415
        • Arena 1614
      • Incheon, Korea, Republic of, 21565
        • Arena 1610
    • Gangwon-do
      • Wonju, Gangwon-do, Korea, Republic of, 26426
        • Arena 1615
  • Latvia
      • Riga, Latvia, 1002
        • Arena 1462
      • Riga, Latvia, 1006
        • Arena 1475
  • Lithuania
      • Vilnius, Lithuania, 8661
        • Arena 1484
  • New Zealand
      • Christchurch, New Zealand, 8011
        • Arena 1601
  • Poland
      • Bydgoszcz, Poland, 85-681
        • Arena 1439
      • Elblag, Poland, 82-300
        • Arena 1486
      • Kielce, Poland, 25-364
        • Arena 1495
      • Krakow, Poland, 31-009
        • Arena 1451
      • Lodz, Poland, 90-302
        • Arena 1438
      • Poznań, Poland, 60-856
        • Arena 1458
      • Rzeszow, Poland, 35-068
        • Arena 1428
      • Sopot, Poland, 81-756
        • Arena 1456
      • Wroclaw, Poland, 54-144
        • Arena 1494
  • Romania
      • Bucharest, Romania, 010719
        • Arena 1491
      • Bucharest, Romania, 020125
        • Arena 1406
      • Bucharest, Romania, 050098
        • Arena 1441
      • Iasi, Romania, 700506
        • Arena 1436
      • Oradea, Romania, 410159
        • Arena 1420
      • Timisoara, Romania, 300002
        • Arena 1405
      • Timisoara, Romania, 300736
        • Arena 1493
  • Russian Federation
      • Krasnoyarsk, Russian Federation, 660022
        • Arena 1500
      • Novosibirsk, Russian Federation, 630091
        • Arena 1504
      • Rostov-on-Don, Russian Federation, 344022
        • Arena 1419
      • Saint Petersburg, Russian Federation, 191015
        • Arena 1498
      • Saint Petersburg, Russian Federation, 191186
        • Arena 1448
      • Samara, Russian Federation, 443063
        • Arena 1465
  • Spain
      • Barcelona, Spain, 08022
        • Arena 1403
      • Barcelona, Spain, 08036
        • Arena 1460
      • Madrid, Spain, 28046
        • Arena 1481
      • Pontevedra, Spain, 36071
        • Arena 1430
      • Santiago de Compostela, Spain, 15706
        • Arena 1432
      • Sevilla, Spain, 41071
        • Arena 1469
  • Ukraine
      • Chernivtsi, Ukraine, 03110
        • Arena 1424
      • Ivano-Frankivsk, Ukraine, 76018
        • Arena 1445
      • Kharkov, Ukraine, 06100
        • Arena 1454
      • Kharkov, Ukraine, 61039
        • Arena 1459
      • Kiev, Ukraine, 01030
        • Arena 1466
      • Kiev, Ukraine, 04201
        • Arena 1411
      • Kyiv, Ukraine, 01030
        • Arena 1408
      • Kyiv, Ukraine, 02091
        • Arena 1506
      • Odessa, Ukraine, 65025
        • Arena 1414
      • Uzhgorod, Ukraine, 88018
        • Arena 1433
      • Vinnytsia, Ukraine, 21029
        • Arena 1501
      • Vinnytsya, Ukraine, 21018
        • Arena 1416
  • United Kingdom
      • London, United Kingdom, E1 1BB
        • Arena 1302
      • Torquay, United Kingdom, TQ2 7AA
        • Arena 1304
      • Wolverhampton, United Kingdom, WV10 0QP
        • Arena 1303
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • Arena 1119
      • Dothan, Alabama, United States, 36305
        • Arena 1133
    • California
      • Thousand Oaks, California, United States, 91360
        • Arena 1143
    • Florida
      • Hollywood, Florida, United States, 33021
        • Arena 1107
      • Miami, Florida, United States, 33134
        • Arena 1138
      • Naples, Florida, United States, 34102
        • Arena 1123
      • Orlando, Florida, United States, 32825
        • Arena 1141
      • Port Orange, Florida, United States, 32127
        • Arena 1106
      • Sweetwater, Florida, United States, 33172
        • Arena 1137
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Arena 1131
      • Hoffman Estates, Illinois, United States, 60169
        • Arena 1139
      • Urbana, Illinois, United States, 61801
        • Arena 1127
    • Maryland
      • Chevy Chase, Maryland, United States, 20815
        • Arena 1113
    • Michigan
      • Traverse City, Michigan, United States, 49686
        • Arena 1142
      • Troy, Michigan, United States, 48098
        • Arena 1111
    • New York
      • Great Neck, New York, United States, 11021
        • Arena 1109
      • Rochester, New York, United States, 14642
        • Arena 1114
    • North Carolina
      • Raleigh, North Carolina, United States, 27612
        • Arena 1118
    • Ohio
      • Cincinnati, Ohio, United States, 45267
        • Arena 1112
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15219
        • Arena 1117
    • Tennessee
      • Germantown, Tennessee, United States, 38138
        • Arena 1105
      • Hermitage, Tennessee, United States, 37076
        • Arena 1102
    • Texas
      • DeSoto, Texas, United States, 75115
        • Arena 1136
      • Houston, Texas, United States, 77030
        • Arena 1121
      • Temple, Texas, United States, 76508
        • Arena 1116
    • Utah
      • Ogden, Utah, United States, 84405
        • Arena 1103
    • Virginia
      • Richmond, Virginia, United States, 23298
        • Arena 1130
      • Roanoke, Virginia, United States, 24014
        • Arena 1128
    • Washington
      • Seattle, Washington, United States, 98101
        • Arena 1115
      • Seattle, Washington, United States, 98195
        • Arena 1101
    • Wisconsin
      • Wauwatosa, Wisconsin, United States, 53226
        • Arena 1108

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants who completed the APD334-003 (NCT02447302) study

Exclusion Criteria:

  • Participants who did not complete the APD334-003 study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Placebo
Drug: Placebo
Experimental: Etrasimod 2 mg
Drug: Etrasimod
Other Names:
  • APD334

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
Time Frame: Up to Week 48 (up to 30 days following discontinuation of the study drug)
A TEAE was defined as any adverse event (AE) that occurred after the first dose of study drug in the APD334-005 (NCT02536404) study, including any AE that started in Study APD334-003 (NCT02447302) and was ongoing, worsened, or ended in Study APD334-005. A SAE was any untoward medical occurrence that at any dose resulted in the following outcomes: death, was life-threatening, required/prolonged hospitalization, disability/incapacity, congenital anomaly/birth defect, and important medical events.
Up to Week 48 (up to 30 days following discontinuation of the study drug)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of Participants Who Achieved Clinical Response
Time Frame: Week 46 (extension study APD334-005)
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Week 46 (extension study APD334-005)
Proportion of Participants Who Achieved Clinical Response at Week 12 in APD334-003 and Maintained Clinical Response at Week 46 in APD334-005
Time Frame: Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
A participant was considered to have achieved clinical response if he/she met the criteria of clinical remission or met criteria of clinical response. Clinical remission was defined as individual subscores of the 3-component Mayo Clinic score as follows: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared to APD334-003 baseline. Clinical response was defined as a decrease in 3-component Mayo Clinic score of ≥ 2 points and at least 30% with either a decrease of rectal bleeding of ≥ 1 or rectal bleeding score of 0 or 1 at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
Proportion of Participants Who Achieved Clinical Remission
Time Frame: Week 46 (extension study APD334-005)
A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Week 46 (extension study APD334-005)
Proportion of Participants Who Achieved Clinical Remission at Week 12 in APD334-003 and Also Maintained Clinical Remission at Week 46 in APD334-005
Time Frame: Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)
A participant was considered to have achieved clinical remission if he/she had: (1) an endoscopy score (using flexible proctosigmoidoscopy) of 0 or 1, (2) a rectal bleeding score of 0, and (3) a stool frequency score of 0 or 1 with a decrease of ≥ 1 point at Week 46 compared with baseline of study APD334-003. A score of 0 = normal and 1 = mild disease.
Week 12 (core study APD334-003) and Week 46 (extension study APD334-005)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Arena Pharmaceuticals

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 25, 2016

Primary Completion (Actual)

November 1, 2018

Study Completion (Actual)

November 1, 2018

Study Registration Dates

First Submitted

August 24, 2015

First Submitted That Met QC Criteria

August 27, 2015

First Posted (Estimate)

August 31, 2015

Study Record Updates

Last Update Posted (Actual)

November 26, 2021

Last Update Submitted That Met QC Criteria

November 24, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • APD334-005

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ulcerative Colitis

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Angola

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe